GEO DataSets

(Submitter supplied) Objectives: We monitored the mRNA expression profiles of peripheral blood cells during treatment with a tumor necrosis factor-a inhibitor, infliximab, in patients with rheumatoid arthritis (RA). Using a DNA microarray analysis, we demonstrated a unique set of genes, with distinct baseline and post-treatment changes in expression between responders and non-responders to infliximab treatment.Methods: Using a customized low-density cDNA microarray and a reliable data collection system, we monitored the mRNA expression profiles of whole blood cells from 18 RA patients before and after the infusion of infliximab for up to 22 weeks. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL5460

72 Samples

Download data: TXT

(Submitter supplied) New and effective therapeutical options are available for the treatment of Rheumatoid Arthritis. One of such treatments is rituximab, and chimeric anti-CD20 antibody that selectively depletes the CD20+ B cell subpopulation. Similar to established anti-TNF alpha therapies, there is a subgroup of RA patients that do not experience significant clinical response. Therefore, one of the major necessities in actual RA therapeutical management is to identify reliable predictors of the response to this therapies. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL2507

23 Samples

Download data: TXT

(Submitter supplied) Introduction of biologics, such as infliximab, to the therapy of rheumatoid arthritis (RA) patients has revolutionized the treatment of this disease. However, biomarkers for predicting the efficacy of the drug at an early phase of treatment for selecting real responders have not been found. We here present predictive markers based on a thorough transcriptome analysis of white blood cells from RA patients. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL4133

68 Samples

Download data: TXT

(Submitter supplied) The goal of this study was to characterize the effects of anti-TNF-alpha treatments on gene expression in peripheral blood mononuclear cells. 8 women were submitted to a 12 weeks treatments with Etanercept or Adalimumab. Peripheral blood mononuclear cells were taken before and after the treatment. The samples from the same patients (obtained before and after the 12 weeks of treatment) were compared on the same microarray. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL1456

8 Samples

Download data: GPR

(Submitter supplied) In 15 patients with rheumatoid arthritis the baseline expression (t=0) of type I IFN-regulated genes was determined in peripheral blood cells (PAXgene) using cDNA-microarrays and compared to levels one month after (t=1) anti-TNF treatment (infliximab). Therefore, we used 43K cDNA microarrays from the Stanford Functional Genomics Facility (http://microarray.org/sfgf/) printed on aminosilane-coated slides containing ~20.000 unique genes. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platforms:

GPL9871 GPL9870 GPL9869

30 Samples

Download data

(Submitter supplied) A genome-scale assessment of peripheral blood B-cell molecular homeostasis in patients with rheumatoid arthritis. Keywords: Rheumatoid Arthritis, B-cells

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL3463

2 Samples

Download data

(Submitter supplied) Identifying gene expression profiles as predictors of a good vs poor response to a combined infliximab/methotrexate treatment in rheumatoid arthritis patients. Keywords: drug response

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL3064

44 Samples

Download data

(Submitter supplied) Synovial tissue mRNA from 21 RA patients and 9 OA patients is hybridized against a common reference sample on lymphochips. Set of arrays organized by shared biological context, such as organism, tumors types, processes, etc. Keywords: Logical Set

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL3262

31 Samples

Download data

(Submitter supplied) Rheumatoid arthritis (RA) is an inflammatory joint disorder that results in progressive joint damage when insufficiently treated. In order to prevent joint destruction and functional disability in RA, early diagnosis and initiation of appropriate treatment with Disease-Modifying Antirheumatic Drugs (DMARDs) is needed. However, in daily clinical practice, patients may initially display symptoms of arthritis that do not fulfil the classification criteria for a definite diagnosis of RA, or any other joint disease, a situation called “Undifferentiated Arthritis” (UA). more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS4195

Platform:

GPL570

25 Samples

Download data: CEL, CHP

Analysis of synovial biopsies obtained by needle arthroscopy from affected knees of patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), or osteoarthritis (OA). Results provide insight into distinct molecular mechanisms underlying SLE arthritis relative to those of OA and RA.

Organism:

Homo sapiens

Type:

Expression profiling by array, count, 5 disease state, 2 gender sets

Platform:

GPL570

Series:

GSE36700

25 Samples

Download data: CEL, CHP

(Submitter supplied) A gene expression profiling sub-study was conducted in which colonic biopsy samples were collected for RNA extraction and hybridization to microarrays from 48 patients with UC who were participating in ACT 1, a placebo-controlled study of infliximab. Gene expression profiles from infliximab responders were compared with those of baseline and infliximab non-responder samples. Infliximab had a significant effect on mRNA expression in treatment responders, with both infliximab dose and duration of treatment having an effect. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

113 Samples

Download data: CEL

(Submitter supplied) Despite the increasing of available drugs in RA, the overall rate of non response is 30 to 40% of treated patients. To optimize the drug prescription and better elaborate the therapeutic strategies, gene profiling in PBMCs was used to predict the responsiveness to anakinra. Thirty two patients treated by anakinra (100mg/day s.c.) and méthotrexate, were categorized as responders whenever a change of Disease Activity Score 28 > 1.2 was obtained at 3 months. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL5215

49 Samples

Download data

(Submitter supplied) Hypersensitivity reactions to medications constitute a growing problem in the clinical practice. In order to study the molecular basis underlying the pathogenesis of non-immediate hypersensitivity reactions to drugs, we characterized the gene expression profiles of PBMCs isolated from patients during the acute phase and upon resolution of the clinical symptoms using a cDNA array technology. Eighty five genes were found to be differentially expressed during the acute phase of drug-induced delayed hypersensitivity reactions. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL7328

26 Samples

Download data: TXT

(Submitter supplied) TNFalpha and IL1beta play a pathogenic role in rheumatoid arthritis. Both cytokines are known to activate cytokine and metalloproteinase secretion by synovial fibroblasts. In the present study, we wanted to investigate whether TNFalpha and IL1beta displayed differential effects on cultured Fibroblast-like Synovial Cells derived from RA patients. Global gene expression analyses indicated that both cytokines induced similar genes in these cells.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

6 Samples

Download data: CEL

(Submitter supplied) TNF antagonists are routinely used in severe rheumatoid arthritis (RA) patients who failed conventional DMARD therapy. According to large clinical trials, the three available drugs (adalimumab, infliximab and etanercept) display similar effects in terms of efficacy, tolerability and side effects. These studies also indicate that about 25% of RA patients treated with TNF-antagonists do not display any significant clinical improvement. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

11 Samples

Download data: CEL

(Submitter supplied) cDNA microarray study of gene expression changes in whole blood from LPS treated rats, 2 and 6 hours after I.P. injection of 5 mg/kg Keywords: time-course

Organism:

Rattus norvegicus

Type:

Expression profiling by array

Platform:

GPL1344

12 Samples

Download data: TIFF

(Submitter supplied) Approximately 30% of rheumatoid arthritis patients achieve inadequate response to anti-TNF biologics. In this study, we sought to identify a blood gene expression biomarker correlating with 12-week response to infliximab in patients with moderate to severe disease. Response was assessed using dynamic contrast-enhanced MRI imaging of the wrist.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL10379

59 Samples

Download data: CEL

(Submitter supplied) Background: Although the use of TNF inhibitors has fundamentally changed the way rheumatoid arthritis (RA) is treated, not all patients respond well. It is desirable to facilitate the identification of responding and non-responding patients prior to treatment, not only to avoid unnecessary treatment but also for financial reasons. In this work we have investigated the transcriptional profile of synovial tissue sampled from RA patients before anti-TNF treatment with the aim to identify biomarkers predictive of response. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL7768

62 Samples

Download data: GPR

(Submitter supplied) Infliximab, an anti-TNF-alpha monoclonal antibody, is an effective treatment for ulcerative colitis (UC) with over 60% of patients responding to treatment and up to 30% reaching remission. The mechanism of resistance to anti-TNF-alpha is unknown. This study used colonic mucosal gene expression to provide a predictive response signature for infliximab treatment in UC. Keywords: drug response

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

30 Samples

Download data: CEL

(Submitter supplied) Infliximab, an anti-TNFa monoclonal antibody, is an effective treatment for ulcerative colitis (UC) inducing over 60% of patients to respond to treatment. Consequently, about 40% of patients do not respond. This study analyzed mucosal gene expression from patients enrolled in ACT1 to provide a predictive response signature for infliximab treatment. Keywords: predictive response signature

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

23 Samples

Download data: CEL